Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report) shares rose 7.8% on Tuesday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares traded hands during trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Performance
The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.86 and a current ratio of 2.86. The business has a 50-day moving average price of $0.19 and a two-hundred day moving average price of $0.19.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Further Reading
- Five stocks we like better than Vyant Bio
- Earnings Per Share Calculator: How to Calculate EPS
- Palantir Cracks $50, Is There Still Time to Get on Board?
- Why Are Stock Sectors Important to Successful Investing?
- Insider Buying Signals Upside for These 3 Stocks
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
